Exosomes derived from vMIP-II-Lamp2b gene-modified M2 cells provide neuroprotection by targeting the injured spinal cord, inhibiting chemokine signals and modulating microglia/macrophage polarization in mice

• Published in: Experimental neurology Vol. 377; p. 114784
• Main Authors: Fu, Gui-Qiang, Wang, Yang-Yang, Xu, Yao-Mei, Bian, Ming-Ming, Zhang, Lin, Yan, Hua-Zheng, Gao, Jian-Xiong, Li, Jing-Lu, Chen, Yu-Qing, Zhang, Nan, Ding, Shu-Qin, Wang, Rui, Li, Jiang-Yan, Hu, Jian-Guo, Lü, He-Zuo
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2024
• Subjects: Exosomes; Lysosomal-associated membrane protein 2b; M2 macrophages; Spinal cord injury; Viral macrophage inflammatory protein II; Viral macrophage inflammatory protein II; M2 macrophages; Lysosomal-associated membrane protein 2b; Spinal cord injury; Exosomes
• ISSN: 0014-4886; 1090-2430
• DOI: 10.1016/j.expneurol.2024.114784

Inflammation is one of the key injury factors for spinal cord injury (SCI). Exosomes (Exos) derived from M2 macrophages have been shown to inhibit inflammation and be beneficial in SCI animal models. However, lacking targetability restricts their application prospects. Considering that chemokine receptors increase dramatically after SCI, viral macrophage inflammatory protein II (vMIP-II) is a broad-spectrum chemokine receptor binding peptide, and lysosomal associated membrane protein 2b (Lamp2b) is the key membrane component of Exos, we speculated that vMIP-II-Lamp2b gene-modified M2 macrophage-derived Exos (vMIP-II-Lamp2b-M2-Exo) not only have anti-inflammatory properties, but also can target the injured area by vMIP-II. In this study, using a murine contusive SCI model, we revealed that vMIP-II-Lamp2b-M2-Exo could target the chemokine receptors which highly expressed in the injured spinal cords, inhibit some key chemokine receptor signaling pathways (such as MAPK and Akt), further inhibit proinflammatory factors (such as IL-1β, IL-6, IL-17, IL-18, TNF-α, and iNOS), and promote anti-inflammatory factors (such as IL-4 and Arg1) productions, and the transformation of microglia/macrophages from M1 into M2. Moreover, the improved histological and functional recoveries were also found. Collectively, our results suggest that vMIP-II-Lamp2b-M2-Exo may provide neuroprotection by targeting the injured spinal cord, inhibiting some chemokine signals, reducing proinflammatory factor production and modulating microglia/macrophage polarization. [Display omitted] •vMIP-II-Lamp2b-M2-Exo can target the injured spinal cord by vMIP-II.•vMIP-II-Lamp2b-M2-Exo can inhibit MAPK and AKT signaling pathways.•vMIP-II-Lamp2b-M2-Exo can reduce proinflammatory factor production.•vMIP-II-Lamp2b-M2-Exo can inhibit M1 microglia/macrophage polarization.•The early administration of vMIP-II-Lamp2b-M2-Exo is a promising strategy for SCI.